The Annual General Meeting of Biovitrum resolved on 24 April 2008 to
issue 284,000 series C shares to secure that the company can fulfill
its commitment according to the performance based, long-term share
program for 2008 ("Share Program 2008"). Furthermore, the Annual
General Meeting resolved to authorize the board of directors to
repurchase all issued series C shares for a price per share
corresponding to the quota value of the Biovitrum share, i.e. in
total SEK 156,000. The series C shares will thereafter be converted
to common shares in the number that is required to secure delivery
under the Share Program 2008.
The board of directors of Biovitrum has resolved to utilize the
authorization for this purpose and to immediately repurchase all
issued series C shares in accordance with the resolution by the
Annual General Meeting on 24 April 2008. Biovitrum does currently not
hold own shares.
For more information please contact:
Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68
Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
[email protected]
About Biovitrum
Biovitrum is a pharmaceutical company with operations in Sweden and
in the UK. The company markets a range of specialist pharmaceuticals.
Using its expertise and experience Biovitrum takes scientific
innovation all the way to the market and to specialist indication
patients with significant medical need. Research expertise and
capabilities include development and production of biotechnology
therapeutics, as well as small molecule discovery and development.
With revenues of approximately SEK 1.3 billion and around 500
employees, Biovitrum is a significant international specialty
pharmaceutical player. Biovitrum's share is listed on the OMX Nordic
Exchange in Stockholm. For more information go to www.biovitrum.com
Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on December 23, 2008 at
08:30 a.m. CET.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.